Skip to content
Menu

UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.

UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.

Read at benzinga.com

← All stock news